Cargando…
Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway
Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (NSCLC) cells. In recent years, the role of the traditional Chinese medicine (TCM) cordycepin (Cor) i...
Autores principales: | Liao, Xiao-Zhong, Gao, Ying, Zhao, Hong-Wei, Zhou, Mi, Chen, Dan-Lei, Tao, Lan-Ting, Guo, Wei, Sun, Ling-Ling, Gu, Chu-Ying, Chen, Han-Rui, Xiao, Zhi-Wei, Zhang, Jia-Xing, He, Mei-Fang, Lin, Li-Zhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843937/ https://www.ncbi.nlm.nih.gov/pubmed/33520990 http://dx.doi.org/10.3389/fcell.2020.609285 |
Ejemplares similares
-
Cordycepin enhances the chemosensitivity of esophageal cancer cells to cisplatin by inducing the activation of AMPK and suppressing the AKT signaling pathway
por: Gao, Ying, et al.
Publicado: (2020) -
Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway
por: Li, Hong-Bo, et al.
Publicado: (2021) -
Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer
por: Wang, Lin, et al.
Publicado: (2020) -
Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer
por: Wang, Lin, et al.
Publicado: (2022) -
Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway
por: Wu, Li-Mei, et al.
Publicado: (2021)